Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: A randomized prospective placebo-controlled trial

Aldo Franco De Rose, Fabrizio Gallo, Matteo Giglio, Giorgio Carmignani

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objectives. To verify the efficacy of mepartricin versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients. Methods. Twenty-six patients with CPPS were included in our study and randomized into two groups of 13 subjects each. Group 1 patients were treated with mepartricin (40 mg daily) and group 2 patients with placebo. All patients underwent treatment for 60 days. At the beginning and end of therapy, all patients underwent evaluation, including a standardized history, physical examination, luteinizing hormone, follicle-stimulating hormone, testosterone, and beta-estradiol measurements, and a National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire. Results. We observed a decrease in the total NIH-CPSI score from 25.0 to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60% and 20% improvement in groups 1 and 2, respectively. A statistically significant decrease was observed with regard to pain (from 11.0 to 4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0 to 5.0 and 10.0 to 9.0, respectively). No statistically significant difference was observed in urinary dysfunctions. The luteinizing hormone, follicle-stimulating hormone, and testosterone values were similar in both groups before and after treatment; the 17-beta-estradiol levels were significantly lower in group 1 compared with group 2 at the end of the study. Conclusions. Mepartricin provides significant symptomatic improvement in men with CPPS compared with placebo. The role of mepartricin in decreasing estrogen plasmatic levels and their concentration in the prostate may account for this clinical improvement.

Original languageEnglish
Pages (from-to)13-16
Number of pages4
JournalUrology
Volume63
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Mepartricin
Prostatitis
Pelvic Pain
Chronic Pain
Placebos
National Institutes of Health (U.S.)
Follicle Stimulating Hormone
Luteinizing Hormone
Testosterone
Estradiol
Physical Examination
Prostate
Estrogens
Therapeutics
History
Quality of Life
Pain

ASJC Scopus subject areas

  • Urology

Cite this

Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome : A randomized prospective placebo-controlled trial. / De Rose, Aldo Franco; Gallo, Fabrizio; Giglio, Matteo; Carmignani, Giorgio.

In: Urology, Vol. 63, No. 1, 01.2004, p. 13-16.

Research output: Contribution to journalArticle

De Rose, Aldo Franco ; Gallo, Fabrizio ; Giglio, Matteo ; Carmignani, Giorgio. / Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome : A randomized prospective placebo-controlled trial. In: Urology. 2004 ; Vol. 63, No. 1. pp. 13-16.
@article{b3a33c51dcb54b3e8282b898b43dbe34,
title = "Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: A randomized prospective placebo-controlled trial",
abstract = "Objectives. To verify the efficacy of mepartricin versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients. Methods. Twenty-six patients with CPPS were included in our study and randomized into two groups of 13 subjects each. Group 1 patients were treated with mepartricin (40 mg daily) and group 2 patients with placebo. All patients underwent treatment for 60 days. At the beginning and end of therapy, all patients underwent evaluation, including a standardized history, physical examination, luteinizing hormone, follicle-stimulating hormone, testosterone, and beta-estradiol measurements, and a National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire. Results. We observed a decrease in the total NIH-CPSI score from 25.0 to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60{\%} and 20{\%} improvement in groups 1 and 2, respectively. A statistically significant decrease was observed with regard to pain (from 11.0 to 4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0 to 5.0 and 10.0 to 9.0, respectively). No statistically significant difference was observed in urinary dysfunctions. The luteinizing hormone, follicle-stimulating hormone, and testosterone values were similar in both groups before and after treatment; the 17-beta-estradiol levels were significantly lower in group 1 compared with group 2 at the end of the study. Conclusions. Mepartricin provides significant symptomatic improvement in men with CPPS compared with placebo. The role of mepartricin in decreasing estrogen plasmatic levels and their concentration in the prostate may account for this clinical improvement.",
author = "{De Rose}, {Aldo Franco} and Fabrizio Gallo and Matteo Giglio and Giorgio Carmignani",
year = "2004",
month = "1",
doi = "10.1016/j.urology.2003.08.006",
language = "English",
volume = "63",
pages = "13--16",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome

T2 - A randomized prospective placebo-controlled trial

AU - De Rose, Aldo Franco

AU - Gallo, Fabrizio

AU - Giglio, Matteo

AU - Carmignani, Giorgio

PY - 2004/1

Y1 - 2004/1

N2 - Objectives. To verify the efficacy of mepartricin versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients. Methods. Twenty-six patients with CPPS were included in our study and randomized into two groups of 13 subjects each. Group 1 patients were treated with mepartricin (40 mg daily) and group 2 patients with placebo. All patients underwent treatment for 60 days. At the beginning and end of therapy, all patients underwent evaluation, including a standardized history, physical examination, luteinizing hormone, follicle-stimulating hormone, testosterone, and beta-estradiol measurements, and a National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire. Results. We observed a decrease in the total NIH-CPSI score from 25.0 to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60% and 20% improvement in groups 1 and 2, respectively. A statistically significant decrease was observed with regard to pain (from 11.0 to 4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0 to 5.0 and 10.0 to 9.0, respectively). No statistically significant difference was observed in urinary dysfunctions. The luteinizing hormone, follicle-stimulating hormone, and testosterone values were similar in both groups before and after treatment; the 17-beta-estradiol levels were significantly lower in group 1 compared with group 2 at the end of the study. Conclusions. Mepartricin provides significant symptomatic improvement in men with CPPS compared with placebo. The role of mepartricin in decreasing estrogen plasmatic levels and their concentration in the prostate may account for this clinical improvement.

AB - Objectives. To verify the efficacy of mepartricin versus placebo with regard to symptom improvement in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a relation between hormonal levels and clinical improvement in these patients. Methods. Twenty-six patients with CPPS were included in our study and randomized into two groups of 13 subjects each. Group 1 patients were treated with mepartricin (40 mg daily) and group 2 patients with placebo. All patients underwent treatment for 60 days. At the beginning and end of therapy, all patients underwent evaluation, including a standardized history, physical examination, luteinizing hormone, follicle-stimulating hormone, testosterone, and beta-estradiol measurements, and a National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire. Results. We observed a decrease in the total NIH-CPSI score from 25.0 to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60% and 20% improvement in groups 1 and 2, respectively. A statistically significant decrease was observed with regard to pain (from 11.0 to 4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0 to 5.0 and 10.0 to 9.0, respectively). No statistically significant difference was observed in urinary dysfunctions. The luteinizing hormone, follicle-stimulating hormone, and testosterone values were similar in both groups before and after treatment; the 17-beta-estradiol levels were significantly lower in group 1 compared with group 2 at the end of the study. Conclusions. Mepartricin provides significant symptomatic improvement in men with CPPS compared with placebo. The role of mepartricin in decreasing estrogen plasmatic levels and their concentration in the prostate may account for this clinical improvement.

UR - http://www.scopus.com/inward/record.url?scp=0742324797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742324797&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2003.08.006

DO - 10.1016/j.urology.2003.08.006

M3 - Article

C2 - 14751338

AN - SCOPUS:0742324797

VL - 63

SP - 13

EP - 16

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -